News

Article

Measuring biomarkers may Identify patients at risk of retinal vascular progression after cataract surgery

Author(s):

Investigators wanted to determine why patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, while some patients do.

(Image Credit: AdobeStock/Alessandro Grandini)

(Image Credit: AdobeStock/Alessandro Grandini)

Pre-existing levels of vascular endothelial growth factor (VEGF) may predispose certain patients who undergo cataract surgery to develop a retinal pathology postoperatively, reported Naren Shetty, MS, who described the study at the American Society of Cataract and Refractive Surgery annual meeting in Boston.1 Shetty is from Narayana Nethralaya Eye Hospital, Bangalore, India.

He and his colleagues pointed out that while patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, some patients do experience worsening. The investigators wanted to determine why that occurs.

To do so, they collected samples of aqueous humor from patients who were undergoing cataract surgeries. Optical coherence tomography was performed preoperatively in all patients and patients found to have non-proliferative and proliferative DR were not included.

The investigators recorded the patients’ diabetic, DR, and hypertension status and followed the patients for 6 to 12 months. They reported conducting testing of a panel of 8 markers on each aqueous humor sample.

In 42 eyes tested, the retinal pathology increased in 5 eyes; Shetty described this as progression to moderate or severe non-proliferative DR and development of diabetic macular edema (DME) compared to the eyes that remained stable.

He and his colleagues reported, “The levels of VEGF in the group with progressive retinal pathology were significantly higher (p<0.05) compared to the group without progressive retinal pathology at the time of cataract surgery.”

Other markers such as interleukin (IL)-6, -10, -1b, and -17A; tumor necrosis factor-a; matrix metalloproteinase 9; and soluble intercellular adhesion molecule-1 did not show significant differences.

The investigators believe that the levels of VEGF present at the time of cataract surgery may result in development of detrimental retinal pathology postoperatively. “Using biomarker testing to stratify patients to enable close monitoring or prophylactic care may help reduce the risk of DME postoperatively,” they concluded.

  1. Conference Abstract or Poster
    Shetty N, Shetty R, Khamar P,et al. Novel biomarker levels to identify risk of retinal vascular progression post cataract surgery. Paper presented at: American Society of Cataract and Refractive Surgery 2024 annual meeting; April 5-8, 2024; Boston, Massachusetts, USA. Session: SPS-202 Retina

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.